

A Phase 1B/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd),
A B7- H3 Antibody-Drug Conjugate (ADC), In combination with Atezolizumab with or Without Carboplatin as
First Line Induction or Maintenance, In Subjects with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
(Ideate-Lung03)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy
volunteers

Inclusion Criteria:

- diagnosis of extensive small cell lung cancer - have not received any prior treatment (first line therapy) - may be unable to do physically strenuous activity but able to walk and do work of a light or sedentary nature, e.g., light house work, office work - agree to use a contraceptive method that is highly effective - see link to clinicaltrials.gov for complete inclusion criteria

Exclusion Criteria:

- any of the following within the past 6 months: cerebrovascular accident, (CVA) transient ischemic attack, (TIA) or another arterial thromboembolic event - uncontrolled or significant cardiovascular disease - history of another cancer in the past 5 years - history of bone marrow, stem cell, or solid organ transplant - women who are pregnant or breastfeeding - see link to clinicaltrials.gov for complete exclusion criteria

Conditions & Interventions

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), small cell lung cancer

More Information

Description: This study is being done to learn more about the safety and effectiveness of ifinatamab deruxtecan (I-DXd) against extensive stage small cell lung cancer.

Study Contact: Manish Patel - patel069@umn.edu

Principal Investigator: Manish Patel

Phase: PHASE1

IRB

Number: STUDY00022784

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.